Hashem Farrokh

Array ( [id] => 16969354 [patent_doc_number] => 11065301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-20 [patent_title] => Pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and use thereof [patent_app_type] => utility [patent_app_number] => 16/093826 [patent_app_country] => US [patent_app_date] => 2016-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 6354 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471222 [patent_doc_number] => 20170058003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'IMMUNOGEN PLATFORM' [patent_app_type] => utility [patent_app_number] => 15/093615 [patent_app_country] => US [patent_app_date] => 2016-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 93691 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15093615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11002562 [patent_doc_number] => 20160199511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'METHODS AND COMPOSITIONS FOR PROTEIN DELIVERY' [patent_app_type] => utility [patent_app_number] => 15/082401 [patent_app_country] => US [patent_app_date] => 2016-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 24754 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15082401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680944 [patent_doc_number] => 20180118814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/560905 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34880 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -83 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16648807 [patent_doc_number] => 10925961 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Vaccines with CD40 ligand as an adjuvant [patent_app_type] => utility [patent_app_number] => 15/559432 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 12 [patent_no_of_words] => 16964 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10997717 [patent_doc_number] => 20160194663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'REPLICATION-DEFECTIVE ARENAVIRUS VECTORS' [patent_app_type] => utility [patent_app_number] => 15/069773 [patent_app_country] => US [patent_app_date] => 2016-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6691 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15069773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12449268 [patent_doc_number] => 09982276 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Penton-mutated, integrin-retargeted adenovirus vectors with reduced toxicity and their use [patent_app_type] => utility [patent_app_number] => 15/067839 [patent_app_country] => US [patent_app_date] => 2016-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 10562 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15067839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185707 [patent_doc_number] => 20180044643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'NON-NEUROINVASIVE VIRUSES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/555873 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 18878 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15555873 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16335581 [patent_doc_number] => 10786519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Methods and materials for treating human immunodeficiency virus infections [patent_app_type] => utility [patent_app_number] => 15/552636 [patent_app_country] => US [patent_app_date] => 2016-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 4318 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15552636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15724345 [patent_doc_number] => 10610588 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-07 [patent_title] => Methods of preventing secondary infections [patent_app_type] => utility [patent_app_number] => 15/549161 [patent_app_country] => US [patent_app_date] => 2016-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 70 [patent_no_of_words] => 24958 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11038879 [patent_doc_number] => 20160235835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-18 [patent_title] => 'INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE' [patent_app_type] => utility [patent_app_number] => 15/007719 [patent_app_country] => US [patent_app_date] => 2016-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11814 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15007719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067665 [patent_doc_number] => 20160264629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'NOVEL ADENOVIRUS ISOLATED FROM TITI MONKEYS' [patent_app_type] => utility [patent_app_number] => 14/996127 [patent_app_country] => US [patent_app_date] => 2016-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 26342 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14996127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436090 [patent_doc_number] => 20170037112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'ANTIBODY CAPABLE OF BINDING TO INFLUENZA VIRUS' [patent_app_type] => utility [patent_app_number] => 14/995902 [patent_app_country] => US [patent_app_date] => 2016-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 6966 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14995902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10774816 [patent_doc_number] => 20160120972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'INACTIVATED DENGUE VIRUS VACCINE WITH ALUMINIUM-FREE ADJUVANT' [patent_app_type] => utility [patent_app_number] => 14/992354 [patent_app_country] => US [patent_app_date] => 2016-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12212 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14992354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11003826 [patent_doc_number] => 20160200775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'VIRUS LIKE PARTICLE COMPRISING MODIFIED ENVELOPE PROTEIN E3' [patent_app_type] => utility [patent_app_number] => 14/990502 [patent_app_country] => US [patent_app_date] => 2016-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 21556 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14990502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15850973 [patent_doc_number] => 10640752 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Salmon gill poxvirus [patent_app_type] => utility [patent_app_number] => 15/539039 [patent_app_country] => US [patent_app_date] => 2015-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 10 [patent_no_of_words] => 23322 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15539039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182631 [patent_doc_number] => 10106819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => Recombinant swinepox virus and vaccines [patent_app_type] => utility [patent_app_number] => 15/536058 [patent_app_country] => US [patent_app_date] => 2015-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7806 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15536058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10987480 [patent_doc_number] => 20160184425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'Efficient mucosal vaccination mediated by the neonatal Fc receptor' [patent_app_type] => utility [patent_app_number] => 14/961938 [patent_app_country] => US [patent_app_date] => 2015-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 28791 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14961938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14485127 [patent_doc_number] => 10329330 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-25 [patent_title] => JC polyomavirus VLP (virus-like particle) with a targeting peptide [patent_app_type] => utility [patent_app_number] => 15/533377 [patent_app_country] => US [patent_app_date] => 2015-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 16931 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10735906 [patent_doc_number] => 20160082056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-24 [patent_title] => 'CANCER THERAPY WITH A PARVOVIRUS COMBINED WITH A BCL-2 INHIBITOR' [patent_app_type] => utility [patent_app_number] => 14/960608 [patent_app_country] => US [patent_app_date] => 2015-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 10723 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14960608 [rel_patent_id] =>[rel_patent_doc_number] =>)